Primary care clinicians routinely counsel patients whose eating patterns reflect diverse cultural traditions. This resource offers practical, evidence-based strategies for supporting balanced nutrition...
A retrospective cohort study examined whether concurrent menopause hormone therapy modifies weight loss and cardiometabolic outcomes among postmenopausal women with overweight or obesity treated with...
An extensive Danish population-based study compared sodium-glucose cotransporter-2 inhibitors with glucagon-like peptide-1 receptor agonists to clarify their relative impact on diabetic foot disease, an...
The FDA has cleared a once-daily oral semaglutide treatment for adults with obesity or overweight and weight-related conditions, based on phase 3 OASIS 4 trial results demonstrating significant mean weight...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
The Trump administration announced a new agreement with pharmaceutical companies Eli Lilly and Company and Novo Nordisk to reduce the cost of obesity medication and expand access to these treatments.
As the clinical use of GLP-1 receptor agonists (RA) expands beyond diabetes and obesity, clinicians must balance emerging cardiometabolic and organ-specific benefits with the challenges of persistent...
Preoperative use of GLP-1 receptor agonists did not increase complications or readmissions following body contouring surgery, suggesting these agents are safe in the perioperative setting.
A retrospective review of patients undergoing elective dental procedures found that dexmedetomidine alone was more often associated with oxygen desaturation, while combining dexmedetomidine with ketamine...
A large prospective study found that specific dietary lignans and whole grain foods are associated with a significantly reduced risk of incident gout, highlighting the potential role of the gut microbiome...
